Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha messenger RNA (PIK3CA mRNA) (PIK3CA mRNA)

PIK3CA mRNA is the messenger RNA transcript that encodes the p110α catalytic subunit of the Phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3K) enzyme. This transcript is a critical intermediary in the PI3K/AKT/mTOR signaling pathway, which governs cell growth, survival, and metabolism (NCBI Gene). In many cancers, including breast, endometrial, and colorectal types, the PIK3CA mRNA often carries gain-of-function mutations (such as H1047R or E545K) that lead to the overproduction of a hyperactive p110α protein, driving oncogenesis (National Cancer Institute). While current clinical therapies primarily focus on small molecule inhibitors of the p110α protein, the mRNA itself is an emerging target for RNA-based therapeutics like siRNAs and antisense oligonucleotides (PubMed). These approaches aim to silence the expression of the oncogenic protein at the pre-translational level, potentially offering higher specificity and reduced toxicity compared to traditional kinase inhibitors (PubMed). Experimental studies have demonstrated that degrading PIK3CA mRNA can effectively inhibit tumor growth and sensitize cancer cells to other treatments (PubMed). Additionally, PIK3CA mRNA expression levels and mutation status serve as vital biomarkers for patient stratification in clinical trials (PubMed). Targeting the mRNA transcript also provides a potential strategy for addressing PIK3CA-related overgrowth spectrum (PROS) disorders (Nature Medicine). Overall, PIK3CA mRNA represents a high-value target for precision medicine in oncology and rare genetic diseases.

Other names

p110alpha mRNAPI3K-alpha mRNAPhosphoinositide-3-kinase catalytic alpha polypeptide mRNAPI3KCA transcript

RNA interference (RNAi) or antisense-mediated degradation of the mRNA transcript, which prevents the translation of the p110α protein and subsequently inhibits the PI3K/AKT/mTOR signaling pathway (PubMed).